City of Hope | Strategic Alliance Partners

February 24, 2022

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

February 18, 2022

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

February 15, 2022

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

February 13, 2022

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

February 10, 2022

The organizations join forces to become one of the largest cancer research and treatment organizations in the country.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss how and/or if any mentors they had during their careers helped them overcome gender-related challenges they experienced.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, share insight on how the corporate culture has changed in oncology practices with regard to gender inequality.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss some of the gender-related obstacles that they experienced throughout their careers as female oncologists.

February 01, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss their early experiences as female oncologists and some of the gender-related challenges they faced during their careers.

January 27, 2022

Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and their advice to young women entering the field.

January 26, 2022

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

January 22, 2022

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

January 14, 2022

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

January 14, 2022

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

January 13, 2022

Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.

January 12, 2022

Cancer Treatment Centers of America's comprehensive cancer centers in Chicago and Atlanta earned the 2021 Guardian of Excellence Award from Press Ganey as top performers in patient experience.

January 10, 2022

It is difficult to know where exactly to begin this commentary regarding the FDA approval to permit commer-cial sales of the Alzheimer disease drug aducanumab-avwa.

December 23, 2021

Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.

December 21, 2021

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.